Aldeyra Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ALDX Nasdaq 2834 www.aldeyra.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aldeyra Therapeutics, Inc.

argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Oct 9th, 2026 10:55 am
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia - Oct 9th, 2026 8:53 am
Here's Why You Should Add LPCN Stock to Your Portfolio Now - Oct 8th, 2026 7:57 am
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Oct 8th, 2026 7:49 am
ETON Stock Surges 108% in Six Months: Here's What You Need to Know - Oct 7th, 2026 9:08 am
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - Oct 6th, 2026 7:55 am
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Oct 6th, 2026 7:30 am
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation - Oct 5th, 2026 8:46 am
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work - Oct 5th, 2026 8:36 am
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections - Oct 1st, 2026 7:42 am
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease - Sep 29th, 2026 9:02 am
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter - Sep 29th, 2026 8:49 am
Merck Inks $2.1B Deal With Chinese Biotech to Expand Oncology Pipeline - Sep 29th, 2026 8:12 am
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Sep 29th, 2026 7:06 am
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease - Sep 29th, 2026 5:00 am
Aldeyra Therapeutics to Host Regulatory Update Webcast - Sep 28th, 2026 2:30 pm
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - Sep 25th, 2026 9:02 am
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down - Sep 24th, 2026 9:50 am
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data - Sep 24th, 2026 7:35 am
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Sep 23rd, 2026 10:08 am